Condition: Classical Hodgkin Lymphoma · Relapsed Cancer · Refractory Cancer · Sponsor: University Health Network, Toronto
This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.
This description comes directly from the study's public registry record.
John Kuruvilla, M.D. · 416-946-2821 · john.kuruvilla@uhn.ca
Always discuss trial participation with your own doctor first.
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04510636